Physician profile
Daniel C Glade
NPI 1821618430
$4,266.66
in general payments reported to CMS, 2019-2025
25 companies · $1,550 in 2025
The $1,550 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,717 · 2025: $1,550.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,596 · Travel and Lodging: $473 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,596.14 |
| Travel and Lodging | $472.52 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,377.71 | 2024-2025 | |
| Janssen Biotech, INC. | $363.22 | 2024-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $337.16 | 2024-2025 | Zoryve |
| Genzyme Corporation | $308.13 | 2024-2025 | |
| Galderma Laboratories, L.P. | $210.55 | 2024-2025 | Nemluvio |
| Lilly USA, LLC | $204.45 | 2024-2025 | Ebglyss, Taltz |
| Ucb, INC. | $197.13 | 2024-2025 | Bimzelx |
| Incyte Corporation | $177.61 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $131.06 | 2024-2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.84 | 2024 | Spevigo |
| Regeneron Healthcare Solutions, INC. | $109.06 | 2024-2025 | Dupixent |
| Dermavant Sciences, INC. | $108.83 | 2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $83.73 | 2024-2025 | Jublia |
| E.R. Squibb & Sons, L.L.C. | $83.25 | 2024 | Sotyktu |
| Pfizer INC. | $80.00 | 2024-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $57.58 | 2024-2025 | |
| Sun Pharmaceutical Industries INC. | $46.31 | 2025 | |
| Revance Therapeutics, INC. | $43.37 | 2024 | Daxxify |
| Merz North America, INC. | $42.29 | 2025 | |
| Organon LLC | $40.96 | 2025 | Vtama |
| Journey Medical Corporation | $38.67 | 2025 | |
| Amgen INC. | $37.81 | 2024-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $31.26 | 2025 | |
| Genentech USA, INC. | $23.87 | 2025 | Xolair |
| Botanix Sb INC | $19.81 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Glade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.